Clinical trials: 2019-nCoV Pneumonia
Coronavirus Disease 2019 (COVID-19)
Evaluation of Silver Nanoparticles for the Prevention of COVID-19
In this research, silver nanoparticles (AgNPs) were tested in vitro and shown to have an inhibitory effect on SARS-CoV-2 infection in cultured cells.
- Trial name
- COVID-19 (NCT04894409)
- Testing
- Mouthwash and nose rinse with the AgNPs solution, Mouthwashes and nose rinse in a conventional way
- Where
- Mexico
- Volunteers
- 231 people, healthy volunteers welcome
- Sponsor
- Cluster de Bioeconomia de Baja California, A.C
2019 nCoV, PD-1
Immunoregulatory Therapy for 2019-nCoV
Sepsis, including viral infections, are major causes of death worldwide. Studies show that in 2017, the number of sepsis patients worldwide reached as high as 48.9 million, of which 11 million patients died.
- Trial name
- NCT04268537
- Testing
- PD-1 blocking antibody+standard treatment, Thymosin+standard treatment, standard treatment
- Volunteers
- 120 people
- Sponsor
- Southeast University, China
Coronavirus Disease 2019 (COVID-19) Pneumonia
Saliva PCR in Pregnant Women with COVID-19
Abstract: Objectives We aim to study the relative viral load using saliva polymerase chain reaction among pregnant women treated with Paxlovid.
- Trial name
- NCT06735300
- Testing
- Nirmatrelvir/Ritonavir (Paxlovid)
- Where
- Taiwan
- Volunteers
- 37 people
- Sponsor
- National Cheng-Kung University Hospital
COVID-19
Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19
This is open-labe randomized multicenter comparative Phase III study conducted in 7 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir for parenteral administration compared with…
- Trial name
- NCT05185284
- Testing
- Favipiravir, Remdesivir
- Where
- 6 sites in Russia
- Volunteers
- 217 people
- Sponsor
- Promomed, LLC
Covid19 Virus Infection
Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)
The human immune system is designed to protect individuals from external sources of infection and internal cell mutation. It works effectively and efficiently until inflammation disturbs its functioning.
- Trial name
- COVID (NCT04790240)
- Testing
- Inflammation (I), Inflammation (II), Inflammation (III)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- All Natural Medicine Clinic, LLC
2019-nCoV
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment…
- Trial name
- NCT04255017
- Testing
- Abidol hydrochloride, Oseltamivir, Lopinavir/ritonavir
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Tongji Hospital
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
Covid19
Early Detection of COVID-19 Using Breath Analysis - Feasibility Study
Early Detection of COVID-19 Using Breath Analysis -Feasibility Study.
- Trial name
- COVID-19 (NCT04602871)
- Testing
- Breath Biopsy
- Where
- 2 sites in Israel
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Scentech Medical Technologies Ltd
COVID-19
Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)
This is a Phase I/II, parallel group, single blinded (participant blinded), randomised study assessing the immunogenicity and safety of AZD1222 and rAd26-S administered as heterologous prime-boost in alternating order in 2 study…
- Trial name
- NCT04760730
- Testing
- AZD1222, rAd26-S
- Where
- United Arab Emirates
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- R-Pharm
Covid19
Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold)
This clinical study is designed to test the efficacy of the Novir 2019-nCoV Immunoglobulin M/Immunoglobulin G Antibody Test in a point-of-care setting to support the increasing need for rapid screening in the detection of…
- Trial name
- NOVIR POC (NCT04902911)
- Testing
- COVID-19 SARS-CoV IgG/IgM antibody rapid test
- Where
- United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Covid19, SARS-CoV 2
Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.
There is an urgent need to evaluate interventions that can prevent the infection with SARS-CoV 2 of healthcare workers at risk. Melatonin is an inexpensive and safe product with protective effect in both bacterial and viral…
- Conditions
- Covid19, SARS-CoV 2, Coronavirus Infection
- Trial name
- MeCOVID (NCT04353128)
- Testing
- Melatonin 2mg
- Where
- Spain
- Volunteers
- 450 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
COVID-19
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
The purpose of this study is to learn about the safety and effects of nirmatrelvir/ritonavir for the potential treatment of COVID-19 rebound.
- Trial name
- NCT05567952
- Testing
- nirmatrelvir, ritonavir
- Where
- 84 sites in United States, Canada and 3 more
- Volunteers
- 436 people
- Sponsor
- Pfizer
Infection Viral
Efficacy and Safety of Longan Extract Spray (P80 Spray) in Volunteers With Coronavirus Disease 2019 (COVID-19)
The objectives of this study are to evaluate efficacy and safety of longan extract spray (P80 spray) in volunteers with coronavirus disease 2019 (COVID19).Patients who infected COVID 19 (positive COVID 19 RT-PCR from nasal swab)…
- Trial name
- NCT04887233
- Testing
- Longan nasal spray
- Volunteers
- 60 people
- Sponsor
- Chulalongkorn University
Graves Disease, COVID-19
To Investigate the Effect of 2019 Novel Coronavirus Infection on the Condition of Patients With Hyperthyroidism
The goal of this observational study is to learn about the correlation between COVID-19 and hyperthyroidism in Patients with hyperthyroidism complicated with COVID-19.
- Trial name
- NCT06204393
- Testing
- Thyroid metabolic index
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Qilu Hospital of Shandong University
Coronavirus Disease 2019
Expanded Access Remdesivir (RDV; GS-5734™)
Disease caused by 2019 Novel Coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Trial name
- NCT04302766
- Testing
- Remdesivir
- Where
- 22 sites in United States, Afghanistan and 6 more
- Sponsor
- U.S. Army Medical Research and Development Command
Covid19
The VIDA After COVID Study
The purpose of this study is to objectively identify and address social determinants of health (SDOH) priorities and barriers in Latino patients who survived or are vulnerable to COVID-19, and to understand the consequences of…
- Trial name
- NCT04945590
- Testing
- Virtual Intervention Program
- Volunteers
- healthy volunteers welcome
- Sponsor
- Mayo Clinic
COVID-19
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
CALAVI US will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
- Trial name
- CALAVI US (NCT04380688)
- Testing
- Acalabrutinib
- Where
- 31 sites in United States
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
COVID-19
Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
Sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization…
- Trial name
- LUNAR (NCT05305651)
- Testing
- Sotrovimab
- Where
- 8 sites in United Kingdom
- Volunteers
- 217 people
- Sponsor
- GlaxoSmithKline
Coronavirus Disease 2019, Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Evaluation of KGR Prescriptions in Suppressing COVID-19 Infection.
These studies offer valuable insights into the potential development of KGR as a novel herbal-based preventive and therapeutic strategy against COVID-19.
- Trial name
- NCT06291883
- Testing
- Kang Guan Recipe (Treat)
- Where
- Taiwan
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sheng-Teng Huang
Coronavirus Disease 2019
Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity
Popular topic: Clinical study on immunogenicity and safety evaluation of sequentially enhanced immunity with recombinant Novel Coronavirus vaccine (CHO cells) Research purpose:Main purpose:To evaluate the immunogenicity of…
- Trial name
- NCT05089045
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.